Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2009 | 06-2009 | 03-2009 | 12-2008 | 09-2008 | |
| Sales | 24,249 | 24,601 | 25,057 | 24,404 | 25,734 |
| Gross Profit | 24,249 | 24,601 | 25,057 | 24,404 | 25,734 |
| Operating Expenses | 33,899 | 47,013 | 33,037 | 32,217 | 28,968 |
| Operating Income | -9,650 | -22,412 | -7,980 | -7,813 | -3,234 |
| Interest Expense | 0 | 0 | 0 | 256 | 176 |
| Other Income | -110 | 618 | 756 | -1,267 | -241 |
| Pre-tax Income | -9,760 | -21,794 | -7,224 | -9,336 | -3,651 |
| Income Tax | -552 | 908 | 665 | 56 | -793 |
| Net Income Continuous | -9,208 | -22,702 | -7,889 | -9,392 | -2,858 |
| Net Income | $-9,208 | $-22,702 | $-7,889 | $-9,392 | $-2,858 |
| EPS Basic Total Ops | -0.22 | -0.55 | -0.19 | -0.23 | -0.07 |
| EPS Basic Continuous Ops | -0.22 | -0.55 | -0.19 | -0.23 | -0.07 |
| EPS Diluted Total Ops | -0.22 | -0.55 | -0.19 | -0.23 | -0.07 |
| EPS Diluted Continuous Ops | -0.22 | -0.55 | -0.19 | -0.23 | -0.07 |
| EBITDA(a) | $-8,539 | $-20,469 | $-6,178 | $-6,015 | $-1,603 |